Sheppard, J. P., Koshiaris, C. ., Stevens, R. ., Lay-Flurrie, S. ., Banerjee, A. ., Bellows, B. K., … McManus, R. J. (2023). The association between antihypertensive treatment and serious adverse events by age and frailty: A cohort study. PLoS Med, 20, e1004223. http://doi.org/10.1371/journal.pmed.1004223
A. Banerjee
First name
A.
Last name
Banerjee
Warren-Gash, C. ., Davidson, J. A., Strongman, H. ., Herrett, E. ., Smeeth, L. ., Breuer, J. ., & Banerjee, A. . (2023). Severe COVID-19 outcomes by cardiovascular risk profile in England in 2020: a population-based cohort study. Lancet Reg Health Eur, 27, 100604. http://doi.org/10.1016/j.lanepe.2023.100604
Dashtban, A. ., Mizani, M. A., Pasea, L. ., Denaxas, S. ., Corbett, R. ., Mamza, J. B., … Banerjee, A. . (2023). Identifying subtypes of chronic kidney disease with machine learning: development, internal validation and prognostic validation using linked electronic health records in 350,067 individuals. EBioMedicine, 89, 104489. http://doi.org/10.1016/j.ebiom.2023.104489
Davidson, J. A., Banerjee, A. ., Douglas, I. ., Leyrat, C. ., Pebody, R. ., McDonald, H. I., … Warren-Gash, C. . (2022). Primary prevention of acute cardiovascular events by influenza vaccination: an observational study. Eur Heart J. http://doi.org/10.1093/eurheartj/ehac737
Mizani, M. A., Dashtban, A. ., Pasea, L. ., Lai, A. G., Thygesen, J. ., Tomlinson, C. ., … Banerjee, A. . (2022). Using national electronic health records for pandemic preparedness: validation of a parsimonious model for predicting excess deaths among those with COVID-19-a data-driven retrospective cohort study. J R Soc Med, 1410768221131897. http://doi.org/10.1177/01410768221131897
Archer, L. ., Koshiaris, C. ., Lay-Flurrie, S. ., Snell, K. I. E., Riley, R. D., Stevens, R. ., … Sheppard, J. P. (2022). Development and external validation of a risk prediction model for falls in patients with an indication for antihypertensive treatment: retrospective cohort study. Bmj, 379, e070918. http://doi.org/10.1136/bmj-2022-070918
Idris, I. ., Zhang, R. ., Mamza, J. B., Ford, M. ., Morris, T. ., Banerjee, A. ., & Khunti, K. . (2021). Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease. Diabetes Obes Metab, 23, 2207–2214. http://doi.org/10.1111/dom.14437
Birkeland, K. I., Bodegard, J. ., Banerjee, A. ., Kim, D. J., Norhammar, A. ., Eriksson, J. W., … Kadowaki, T. . (2021). Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab, 23, 75–85. http://doi.org/10.1111/dom.14189
Idris, I. ., Zhang, R. ., Mamza, J. B., Ford, M. ., Morris, T. ., Banerjee, A. ., & Khunti, K. . (2022). Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting. Diabetes Obes Metab. http://doi.org/10.1111/dom.14799
Dashtban, A. ., Mizani, M. A., Denaxas, S. ., Nitsch, D. ., Quint, J. ., Corbett, R. ., … Banerjee, A. . (2022). A retrospective cohort study measured predicting and validating the impact of the COVID-19 pandemic in individuals with chronic kidney disease. Kidney Int. http://doi.org/10.1016/j.kint.2022.05.015